Abstract:Objective: To observe the efficacy and safety of combined thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) and urokinase (UK) on patients with acute cerebral infarction. Method: Eighty-one patients with acute cerebral infarction (< 6 hours from onset) were recruited and randomly allocated into four groups: combined thrombolysis group (n = 20), rt-PA group (n = 22), UK group (n=18), and control group (n = 21). The patients in combined thrombolysis group received rt-PA 20 mg and UK 300 000 - 500 000 IU; the patients in rt-PA group received rt-PA 0.9 mg/kg intravenously; the patients in UK group received UK 10 000 - 20 000 IU/kg (patients with body weight > 75 kg received the same dose of medication as 75 kg), and the maximum dose of UK was 1 500 000 IU; the patients in the control group received to no thrombolytic drugs. The outcome score were evaluated according to the National Institute of Health Stroke Scale (NIHSS) before treatment and four weeks after symptom onset, and to evaluate hemorrhagic transformation, recurrent infarction, and death as the safety indicators. Results: 1Before treatment the NIHSS scores in the combined thrombolysis, rt-PA, UK, and control groups were 18.1 ± 3.6, 17.9 ± 3.6, 18.0 ± 3.4, and 17.3 ± 4.0, respectively, and after treatment they were 9.1 ± 5.6, 8.8 ± 5.5, 9.6 ± 5.2, and 14.1 ±4.6, respectively. There were significant differences in each group before and after treatment (P <0.01), and also between the 3 thrombolysis groups and the control group (P < 0.01); but there were no significant differences between each other of the 3 thrombolysis groups. 2The total effective rates in the 4 groups but were 85.0% (17/20), 86.4% (19/22), 83.3% (15/18), and 42.9% (9/21), respectively. As compared between the 3 thrombolysis groups with the control group, there were significant differences (P < 0.05); and there were no significant differences among the 3 thrombolysis groups (P >0. 05). 3One patient had new attack of cerebral infarction, and 1 patient had hemorrhagic transformation within 24 hours after thrombolytic therapy in the combined thrombolytic group; 3 patients had hemorrhagic transformation in the rt-PA group; 1 patient had new attack of cerebral infarction in the UK group; 2 patients had hemorrhagic transformation, and 1 of them died. One patient had new attack of cerebral infarction, and 1 patient was died in the control group. Conclusion: The combined thrombolytic therapy with low-dose rt-PA and UK for the treatment of acute cerebral infarction is safe and effective.

Clinical Study of Therapy for Acute Cerebral Infarction Through Local Intra-Arterial Infusion with Recombinant Streptokinase

Study of intravenous thrombolysis with recombinant tissue plasminogen activator(rtPA)in isolatedpenetrating artery territory infarcts

Effect and safety of rt-PA combined with Hydroxyethyl starch in the treatment of acute cerebral infarction

Combined thrombolytic therapy with low-dose recombinant tissue plasminogen activator and urokinase for patients with acute cerebral infarction

Intra-Arterial Local Thrombolysis for Hyperacute Cerebral Infarction with Recombinant Tissue Plasminogen Activato

Clinical study on intra-arterial and intravenous thrombolysis in acute cerebral infarction

Inter-arterial Thrombolysis Using Rt-Pa for Acute Cerebral Ischemic Stroke

Local Intra-Arterial Thrombolysis in Acute Ischemic Stroke of the Anterior Circulation

Local Intra-arterial Thrombolysis in Acute Stroke due to Middle Cerebral Artery Occlusion

Intra-arterial Thrombolysis with Urokinase in Acute Cerebral Infarction Based on Computed Tomography Perfusion Imaging Within a 6-9 H Window: an Efficacy and Safety Analysis

The Clinical Study on the Treatment for Acute Cerebral Infarction by Intra-Arterial Thrombolysis Combined with Mild Hypothermia.

Intravenous Thrombolysis with R-Tpa and UK for Treating Acute Cerebral Infarction

Investigating of the indiction of selective intra-arterial thrombolysis for acute ischemic cerebral stroke

Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction

The Clinical Study of Thrombolysis with rt-PA in Acute Ischemic Stroke

Angiographic efficacy of recombinant streptokinase in thrombolytic therapy of acute thromboembolic stroke of swine

Clinical Study the Effects of Lumbrukinase for Treatment of Acute Cerebral Infarction

Clinical Analysis of Cerebral Infraction Treated by Super-Early Intraarterial Thrombolytic Therapy

Comparison and Research on Supperselected Intraaterial Thrombolysis and Venous Thrombolysis in Treating Acute Cerebral Infarction

Intravenous thrombolysis with urokinase for acute cerebral infarctions(within 6h from symptom onset)

Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke-a Single Center Retrospective Study